📊 MYGN Key Takeaways
Is Myriad Genetics Inc. (MYGN) a Good Investment?
Myriad Genetics demonstrates a structurally sound business model with 68.7% gross margins, but faces severe operational challenges with negative operating income, unprofitable net results, and significant free cash flow deterioration (-$58.0M). With revenue declining YoY and an annual cash burn exceeding available liquidity runway, the company requires urgent operational restructuring and cannot sustain current CapEx levels without fundamental profitability improvements.
Despite strong gross margins and a solid liquidity profile, Myriad Genetics is generating steep operating and net losses with markedly negative year-over-year earnings trends. Free cash flow remains negative and operating income deeply in the red, implying core operations are not yet self-funding. Until sustained operating margin improvement and positive operating cash flow are evident, fundamentals skew unfavorable.
Myriad Genetics Inc. Key Strengths (MYGN)
- Strong gross margin of 68.7% indicates viable underlying product economics and pricing power
- Conservative debt structure with 0.36x Debt/Equity ratio and $124.4M cash provides financial flexibility
- Solid liquidity position with 2.40x current ratio and 2.19x quick ratio supports near-term obligations
- High gross margin indicating pricing power and IP
- Strong liquidity with low leverage (current and quick ratios >2x, D/E 0.33x)
- Cash balance exceeds long‑term debt, providing runway
MYGN Stock Risks: Myriad Genetics Inc. Investment Risks
- Company is unprofitable at operating level (-15.3% margin) and net level (-17.0% margin) with deteriorating ROE (-10.1%) and ROA (-5.1%)
- Negative free cash flow of -$58.0M combined with declining revenue creates unsustainable burn trajectory with approximately 2-year cash runway at current rate
- Operating expenses exceed revenue generation capabilities despite strong gross margins, suggesting structural cost issues or failed investment thesis in current product mix
- Persistent operating losses and negative net margin erode equity
- Weak revenue trend and potential mix/reimbursement pressure
- Turnaround execution risk leading to continued cash burn
Key Metrics to Watch
- Operating cash flow inflection and path to cash flow breakeven
- Revenue stabilization or growth acceleration to justify continued capital expenditures
- Operating expense rationalization and progress toward operating profitability
- Operating cash flow (TTM)
- Operating margin (TTM)
Myriad Genetics Inc. (MYGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.40x current ratio provides a solid financial cushion.
MYGN Profit Margin, ROE & Profitability Analysis
MYGN vs Healthcare Sector: How Myriad Genetics Inc. Compares
How Myriad Genetics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Myriad Genetics Inc. Stock Overvalued? MYGN Valuation Analysis 2026
Based on fundamental analysis, Myriad Genetics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Myriad Genetics Inc. Balance Sheet: MYGN Debt, Cash & Liquidity
MYGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Myriad Genetics Inc.'s revenue has remained relatively flat over the 5-year period, with a 2% decline. The most recent EPS of $-3.18 indicates the company is currently unprofitable.
MYGN Revenue Growth, EPS Growth & YoY Performance
MYGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $195.9M | -$100.0K | $0.00 |
| Q3 2025 | $205.7M | -$100.0K | $-0.24 |
| Q2 2025 | $211.5M | -$100.0K | $-0.41 |
| Q1 2025 | $195.9M | -$100.0K | $0.00 |
| Q3 2024 | $191.9M | -$22.1M | $-0.24 |
| Q2 2024 | $183.5M | -$26.0M | $-0.41 |
| Q1 2024 | $181.2M | -$26.0M | $-0.29 |
| Q3 2023 | $156.4M | -$14.1M | $-0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Myriad Genetics Inc. Dividends, Buybacks & Capital Allocation
MYGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Myriad Genetics Inc. (CIK: 0000899923)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MYGN
What is the AI rating for MYGN?
Myriad Genetics Inc. (MYGN) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MYGN's key strengths?
Claude: Strong gross margin of 68.7% indicates viable underlying product economics and pricing power. Conservative debt structure with 0.36x Debt/Equity ratio and $124.4M cash provides financial flexibility. ChatGPT: High gross margin indicating pricing power and IP. Strong liquidity with low leverage (current and quick ratios >2x, D/E 0.33x).
What are the risks of investing in MYGN?
Claude: Company is unprofitable at operating level (-15.3% margin) and net level (-17.0% margin) with deteriorating ROE (-10.1%) and ROA (-5.1%). Negative free cash flow of -$58.0M combined with declining revenue creates unsustainable burn trajectory with approximately 2-year cash runway at current rate. ChatGPT: Persistent operating losses and negative net margin erode equity. Weak revenue trend and potential mix/reimbursement pressure.
What is MYGN's revenue and growth?
Myriad Genetics Inc. reported revenue of $200.4M.
Does MYGN pay dividends?
Myriad Genetics Inc. does not currently pay dividends.
Where can I find MYGN SEC filings?
Official SEC filings for Myriad Genetics Inc. (CIK: 0000899923) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MYGN's EPS?
Myriad Genetics Inc. has a diluted EPS of $-0.36.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is MYGN's fundamental grade?
Based on our AI fundamental analysis in May 2026, Myriad Genetics Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is MYGN stock overvalued or undervalued?
Valuation metrics for MYGN: ROE of -10.1% (sector avg: 15%), net margin of -17.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is MYGN's AI grade for 2026?
Our dual AI analysis gives Myriad Genetics Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MYGN's free cash flow?
Myriad Genetics Inc.'s operating cash flow is $-15.7M, with capital expenditures of $42.3M. FCF margin is -28.9%.
How does MYGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -17.0% (avg: 12%), ROE -10.1% (avg: 15%), current ratio 2.40 (avg: 2).